Dominique Surleraux
Fondateur chez BCI Pharma SAS
Profil
Dominique Surleraux is the founder of BCI Pharma SAS, a company founded in 2013.
He currently holds the titles of President, Chief Executive Officer, and Director at BCI Pharma SAS.
Prior to founding BCI Pharma SAS, Dr. Surleraux worked as the Vice President of Medicinal Chemistry at Idenix Pharmaceuticals LLC.
Dr. Surleraux obtained a doctorate degree from Facultés Universitaires Notre-Dame de la Paix and a graduate degree from Université des Sciences et Technologies de Lille.
Postes actifs de Dominique Surleraux
| Sociétés | Poste | Début |
|---|---|---|
BCI Pharma SAS
 BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | Fondateur | 01/03/2013 |
Anciens postes connus de Dominique Surleraux
| Sociétés | Poste | Fin |
|---|---|---|
| IDENIX PHARMACEUTICALS INC | Directeur Technique/Scientifique/R&D | - |
Formation de Dominique Surleraux
| Université des Sciences et Technologies de Lille | Graduate Degree |
| Facultés Universitaires Notre-Dame de la Paix | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
BCI Pharma SAS
BCI Pharma SAS Miscellaneous Commercial ServicesCommercial Services BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | Commercial Services |